brachytherapy seeds

TheraSeed® Palladium 103, Model 200

Industry benchmark
Unrivaled, long-term clinical experience
Exclusive design; distinctive concave end cups
16.9 day half life; 20-23 keV principle energy
Wide range of available activities

AgX100® – Iodine 125, Model AgX100

Designed after the recognized I-125 seed industry benchmark with long-term clinical experience
Longer, more stable silver core for improved image clarity
59.4 day half life; 27-35 keV principle energy
Wide range of available activities

Dosimetric characterization of TheraSeed and AgX100 include Monte Carlo and experimental studies conducted in accordance with the AAPM Task Group 43 update (TG43U1). For references, please visit the AAPM Sealed Source Device Registry: http://rpc.mdanderson.org/RPC/home.htm
TheraSeed: http://rpc.mdanderson.org/rpc/BrachySeeds/TheraSeed_model_200.htm
AgX100: http://rpc.mdanderson.org/rpc/BrachySeeds/AgX100.htm

¹Rivard, et al., “Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations”, Med Phys. 31, 663-674, (2004)

Content intended for the USA. Indications may vary in different countries; please either consult the appropriate IFU or your local distributor.

brachytherapy seeds

Trusted Experience and Quality

TheraSeed® Palladium 103, Model 200

AgX100® – Iodine 125, Model AgX100